Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27363990 | 0.94 | F2 (0.51) | F2TDP1PPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL14872759 | 0.89 | TDP1 (0.53) | F2TDP1ALDH1A1KMT2AHTR6 | |
| SCHEMBL4127164 | 0.89 | PPARG (0.56) | F2TDP1PPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL27657953 | 0.85 | F2 (0.49) | F2TDP1ALDH1A1KMT2AHTR6 | |
| SCHEMBL28286017 | 0.82 | PGR (0.54) | TDP1ALDH1A1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL29673550 | 0.82 | ENPP3 (0.56) | KMT2AGPR17MAPT | |
| SCHEMBL22187319 | 0.82 | ENPP3 (0.56) | KMT2AGPR17MAPT | |
| SCHEMBL30617915 | 0.82 | CA12 (0.57) | KMT2AMAPT | |
| SCHEMBL30617914 | 0.81 | GPR17 (0.55) | ALDH1A1SMN1; SMN2KMT2AHTTGPR17 | |
| SCHEMBL22187506 | 0.81 | GPR17 (0.55) | F2ALDH1A1SMN1; SMN2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928475-B1 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES | RIBOSCIENCE LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-7608599-B2 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| EP-0773235-B1 | Polymerization of alpha-olefins | MITSUBISHI CHEM CORP (JP) | 1999-05-26 | — | — | EP | disclosed |
| EP-0759445-B1 | Catalyst for olefin polymerization and method for producing olefin polymers using the same | MITSUBISHI CHEM CORP (JP) | 1999-03-17 | — | — | EP | disclosed |
| EP-0773235-A1 | Polymerization of alpha-olefins | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-05-14 | — | — | EP | disclosed |
| EP-0759445-A1 | Catalyst for olefin polymerization and method for producing olefin polymers using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-02-26 | — | — | EP | disclosed |
| EP-0015518-B1 | METHOD FOR IMMUNOLOGICAL ANALYSIS OF TRACE COMPONENTS | FUJI PHOTO FILM CO., LTD. (JP) | 1983-07-20 | — | — | EP | disclosed |
| US-4337063-A | PHOTOCHEMICAL METHOD | FUJI PHOTO FILM CO., LTD. (JP) | 1982-06-29 | — | — | US | disclosed |
| US-4331444-A | Competitive immunoassay using silver halide fogging agent | FUJI PHOTO FILM CO., LTD. (JP) | 1982-05-25 | — | — | US | disclosed |
| EP-0015519-A1 | Method for immunological analysis | FUJI PHOTO FILM CO., LTD. (JP) | 1980-09-17 | — | — | EP | disclosed |
| EP-0015518-A1 | Method for immunological analysis of trace components | FUJI PHOTO FILM CO., LTD. (JP) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | F2 904/4885TDP1 1929/4885PPARG 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.